Veterinary Drug Delivery Research Articles

New Trends in Drug Delivery Systems for Veterinary Applications.

The veterinary pharmaceutical industry has shown significant growth in recent decades. Several factors contribute to this increase as the demand for the improvement of the quality of life of both domestic and wild animals, together with the need to improve the quality, productivity, and safety of foodstuffs of animal origin. The goal of this work was to identify the most suitable medicines for animals that focus on drug delivery routes as those for humans, although they may have different devices, such as collars and ear tags. Recent advances in drug delivery systems for veterinary use are discussed, both from academic research and the global market. The administration routes commonly used for veterinary medicines are also explored, while special attention is given to the latest technological trends to improve the drug performance, reducing the number of doses, animal stress, and side effects. Drug delivery system in veterinary decreased the number of doses, side effects, and animal stress that are a small fraction of the benefits of veterinary drug delivery systems and represent a significant increase in profit for the industry; also, it demands investments in research regarding the quality, safety, and efficacy of the drug and the drug delivery systems.

Business models of the French veterinary offices in rural areas and regulation of veterinary drug delivery

French veterinarians are authorised to both prescribe and deliver drugs. This situation of conflict of interest is sometimes denounced as a potential source of over-prescription and overuse of veterinary antimicrobials, even if no evidence is available up to now. This leads to regular calls for separating prescription from drug delivery, even if the consequences of such separation are unknown. The present work aims at describing the business model of French veterinary offices and the expected impact of separation on those offices. A dataset of 15 million observations was built with structural and accounting data collected for the period 2015–2017 from French mixed veterinary offices. Results of the baseline scenario indicate that veterinary offices’ profit generated from farm animal activities is mainly driven by drug delivery (about 70%), while profit from companion animal activities is mainly driven by medical acts (i.e., consultation and advice, surgery, and laboratory analysis) and sale of accessory products (about 65%). The net margin rate is higher than 25% for all activities, except for material selling. If drug delivery or sales associated with a medical act (same day, same client, and same animal) do not require additional human resources (alternative scenario), the net margin is reduced for medical acts. For both scenarios, a high variability is observed between veterinary offices. This shows that the profit of each activity is highly driven by time spent on the activities. Our results suggest that, in the case of restrictions on drug delivery by veterinarians, their profit may dramatically decrease, especially for farm animal practitioners and those with low medical acts profitability. Further work is needed to account for the high diversity of situations faced by veterinary offices and the sensitivity of their profitability to production costs.

Veterinary drug delivery

Veterinary drug delivery

Veterinary Pharmacy, a Dismissed Necessity

Veterinary pharmaceuticals play an important role in human and animal health. Although some dosage forms are specially designed for use in animals (e.g. ear tags, collars and darts), most drug delivery systems (including nano-carriers and controlled drug delivery systems) are common between animals and human (1). A successful drug development process (for human or animal use), from initial drug discovery to market, requires skill and knowledge in different areas of science of which some disciplines (e.g. pharmaceutics) are exclusively covered in pharmacy undergraduate or postgraduate programs. Pharmaceutics is the art, science and technology of drug delivery system design, manufacture and control and include pre-formulation studies, dosage form design, pharmaceutical processing, quality control, quality assurance, biopharmaceutics and etc. Therefore, like human medicine, pharmacists are expected to design, manufacture and control veterinary drug delivery systems at both levels of pharmaceutical companies or compounding in a pharmacy. This is not what is happening in most veterinary pharmaceutical companies and almost all veterinary-based pharmacies in here, where the professions are performed by veterinary medical doctors (Doctor of Veterinary Medicine, DVM) (2). The educational program in veterinary medicine (DVM) is clinical-based and is focused on prevention, diagnosis and treatment of animal diseases (3), the same perspective as that designed for the physicians (MD). While, there is not such authorization for physicians to act the same in humanoriented pharmaceutical systems. On the other hand, formulation of many drugs for human use is seldom suited for animal administration (4). Design and preparation of veterinary drug delivery systems requires different considerations and is facing more challenges than that of human formulations and cannot be implemented based on human data only. Following are some special considerations (1, 5):

Biodegradable polymers and their potential use in parenteral veterinary drug delivery systems

Biodegradable polymers have been extensively studied for numerous drug delivery systems for human health purposes. The ever-increasing value of animals to human society allows the application of pharmaceutical developments in the veterinary field from those developed in human medicine. Although many similarities between the human and animal health industries exist there are also notable differences. This paper provides an insight into the animal health market with regard to the challenges and special considerations associated with veterinary drug delivery. It also gives an overview of biodegradable polymers that are used or have been tested in the veterinary field. The purpose of this paper is to highlight some recent developments in this area and to investigate the directions in which veterinary pharmaceutics is heading. In particular, examples of existing biodegradable veterinary drug delivery systems are presented together with applications including intravaginal devices, injectables and implantable systems.

Potential applications of chitosan in veterinary medicine

Chitosan is a partially deacetylated polymer obtained from the alkaline deacetylation of chitin which is a glucose-based unbranched polysaccharide widely distributed in nature as the principal component of exoskeletons of crustaceans and insects as well as of cell walls of some bacteria and fungi. Chitosan exhibits a variety of physicochemical and biological properties resulting in numerous applications in fields such as waste and water treatment, agriculture, fabric and textiles, cosmetics, nutritional enhancement, and food processing. In addition to its lack of toxicity and allergenicity, and its biocompatibility, biodegradability and bioactivity make it a very attractive substance for diverse applications as a biomaterial in pharmaceutical and medical fields, where it has been used for systemic and local delivery of drugs and vaccines. It also has bioactive properties in its own right. This paper reviews current veterinary applications for chitosan including wound healing, bone regeneration, analgesic and antimicrobial effects. It also discusses the potential application of chitosan to drug and vaccine delivery in veterinary species. Given the restrictions imposed by financial and animal restraint considerations, especially in farming applications, the veterinary drug delivery areas most likely to benefit from chitosan are the delivery of chemotherapeutics such as antibiotics, antiparasitics, anaesthetics, painkillers and growth promotants to mucosal epithelium for absorption for local or systemic activity, and the delivery of immunomodulatory agents to the mucosal associated lymphoid tissue for induction or modulation of local immune responses. The properties of chitosan expected to enhance these functions are discussed, and the future research directions in this field are indicated.